Thomas Marron, MD
Enriched profileProfessor of Medicine (Hematology and Medical Oncology) and Professor of Immunology and Immunotherapy; Director, Early Phase Trials Unit (EPTU); Associate Director for Translational Research, Mount Sinai Tisch Cancer Center · Icahn School of Medicine at Mount Sinai
Thomas Marron is Professor of Medicine (Hematology and Medical Oncology) and Professor of Immunology and Immunotherapy; Director, Early Phase Trials Unit (EPTU); Associate Director for Translational Research, Mount Sinai Tisch Cancer Center at Icahn School of Medicine at Mount Sinai. OpenAlex indexes 399 publications with 12,205 citations (h-index 43); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 1 Sept 2026
Thomas Marron, MD PHD, is Professor of Medicine (Hematology and Medical Oncology) and Professor of Immunology and Immunotherapy at Icahn School of Medicine at Mount Sinai / Mount Sinai Tisch Cancer Center. The public record shows 399 publications with 12,205 citations (h-index 43), centered on Lung Cancer (NSCLC/SCLC), Colorectal Cancer, Hepatobiliary Cancer. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 22 companies, 2 NIH-funded awards (2023–2026).
- Most recent indexed publication: 2026 · Journal for immunotherapy of cancer
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 32 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- Immunoprevention for High-risk Lung Lesions
Sponsor: Robert Samstein
- A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation
Sponsor: Icahn School of Medicine at Mount Sinai
Industry payments
Updated 1 Sept 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year202514 payments$13,296openpaymentsdata.cms.gov ↗
- Merck Sharp & Dohme LLCProgram year20259 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
39.2%Serotonin-3 Receptor Antagonist21.6%Ondansetron Odt100%Part D<11 patientsH2 blocker17.6%Famotidine100%Part D<11 patientsCancer & immunology
21.6%Kinase inhibitor21.6%Tagrisso100%Part D<11 patientsNervous system
21.6%Phenothiazine12.8%Prochlorperazine Maleate100%Part D<11 patientsOther antidepressants8.8%Mirtazapine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 1 Sept 2026
2 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Breaking the Myeloid-Stromal Axis to Treat Colorectal Cancer
Icahn School of Medicine at Mount Sinai
FY2026$697,131R01CA308427 - Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
Icahn School of Medicine at Mount Sinai
FY2026$658,328R01CA277479 - Type 2 immunity: a primitive response to epithelial injury that shapes bone marrow and lung myeloid crosstalk
Icahn School of Medicine at Mount Sinai
FY2025$658,328R01CA277479
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Expert opinion on burning questions in cancer myeloid cell biology.
Journal for immunotherapy of cancer
Letter2026 - Author Correction: Innovative approaches for lung cancer screening and interception.
Nature reviews. Clinical oncology
Erratum2026 - Innovative approaches for lung cancer screening and interception.
Nature reviews. Clinical oncology
Review2026 - Fecal microbiota transplantation plus immunotherapy in non-small cell lung cancer and melanoma: the phase 2 FMT-LUMINate trial.
Nature medicine
Clinical Trial2026 - Humoral IgG1 responses to tumor antigens underpin clinical outcomes in immune checkpoint blockade.
Nature medicine
Article2026
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/thomas-marron-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/thomas-marron-8969a252
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Other
scholars.mssm.edu/en/persons/thomas-marron
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Mentions by others
where others cite or feature them- Apple Podcasts
podcasts.apple.com/us/podcast/the-oncology-insights-podcast/id1823946880
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →podcasts.apple.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- MD
PhD (Icahn School of Medicine at Mount Sinai)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - Board Certified
Internal Medicine/Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →zocdoc.com ↗
Editorial & leadership roles
journal and society appointments- Director
Early Phase Trials Unit (EPTU), Mount Sinai Tisch Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.mountsinai.org ↗ - Associate Director for Translational Research
Mount Sinai Tisch Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.mountsinai.org ↗ - Member
Center for Thoracic Oncology, Mount Sinai (treats NSCLC, SCLC, malignant pleural mesothelioma)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →google.com ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →google.com ↗
Secondary affiliations
appointments beyond the home institution- Human Immune Monitoring Center
Icahn School of Medicine at Mount Sinai (affiliated researcher; director is Miriam Merad, not Marron)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗ - Marc and Jennifer Lipschultz Precision Immunology Institute
Icahn School of Medicine at Mount Sinai
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.mssm.edu ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →podcasts.apple.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
- Podcast guest
BioPlus Specialty Pharmacy "Working in Oncology" podcast/video series, discussing role as Director of Early Phase Trials Unit
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →blog.bioplusrx.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Jonathan Halperin, MD
Icahn School of Medicine at Mount Sinai
Fred Lublin, MD
Icahn School of Medicine at Mount Sinai
Sundar Jagannath, MD
Icahn School of Medicine at Mount Sinai